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Abstract The hemoflagellate protozoan parasite Trypanosoma
cruzi is the causative agent of Chagas disease, a progressive fatal
cardiomyopathy widespread in South and Central America.
Here, we postulate that the preferential colonization of
cardiomyocytes by T. cruzi may reflect the role of myoglobin
(Mb) as a nitric oxide (NO) scavenger, protecting the parasite
from the trypanocidal effects of NO. The proposal of this novel
function of Mb is based on knowledge that ferrous oxygenated
Mb reacts rapidly and irreversibly with NO yielding nitrate and
ferric oxidized Mb, which is reduced back to the physiologically
active form by an intracellular reductase. The postulated
protective role of Mb on the viability of T. cruzi is reminiscent
of that postulated for hemoglobin in protecting intraerythrocytic
Plasmodia from the parasiticidal effect of NO. ß 2001 Feder-
ation of European Biochemical Societies. Published by Elsevier
Science B.V. All rights reserved.
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The hemo£agellate protozoan parasite Trypanosoma cruzi,
the causative agent of Chagas disease, a¥icts more than 20
million people in Central and South America. A much larger
population is considered at risk worldwide. Acute Chagas
disease is a generalized infection with lesions located any-
where in the mammalian host, consisting of parasite-related
focal lesions. However, acute Chagas disease is only rarely
fatal in naturally infected humans (5% or less). The majority
of infected people in endemic areas present the intermediate
elusive form of Chagas disease; a fraction of these (approx-
imately 30%) will evolve to the progressive fatal chronic car-
diac form. Remarkably, Chagas disease, for which no therapy
is currently available, represents the main cause of heart at-
tack among infected people [1].
T. cruzi has a complex life cycle, involving a triatomine bug
as hematophagous vector and a mammalian host. It is usually
transmitted to humans by contamination of abraded skin,
with the infective, penetrative trypomastigote forms that occur
in the feces of infected bugs. Having gained access to the
mammalian host, trypomastigotes penetrate non-phagocytic
or phagocytic cell lines, transform to the amastigote stage
which multiplies, and eventually emerge from ruptured cells
as trypomastigotes. Parasites penetrate again in cells to renew
the cycle of intracellular division. A fraction of trypomasti-
gotes may circulate in the blood to be picked up by triatomine
bugs taking a blood meal. Transmission by transfusion of
infected blood and by renal or heart transplantation is taken
as epidemiologically signi¢cant [1].
Nitric oxide (NO) has been reported to display antiparasitic
activity [2]. Macrophages from Trypanosoma-infected mice
produce high levels of NO to kill developing trypomastigotes
[3^5]. Levels of NO and NO metabolites increase during T.
cruzi invasion of cardiomyocytes [6] which express the main
isoforms of NO synthase [7,8]. Consistently, an inverse rela-
tionship has been observed between trypanosomiasis and NO
levels, in vivo and in vitro [9^11]. Moreover, susceptibility to
T. cruzi in mice de¢cient in inducible NO synthase [12] in-
creases signi¢cantly. Treatment of infected mice with inhibi-
tors of inducible NO synthase has adverse e¡ects, while NO
donors kill T. cruzi trypomastigotes [9,10]. Furthermore, NO
has been reported to play a role in apoptosis induction during
the acute phase of T. cruzi infection in mice [13], in the re-
duction of the host immune response [13] and in parasite cell
in£ux, contributing to the pathogenesis of chagasic cardiomy-
opathy [14,15].
NO may a¡ect T. cruzi by chemical modi¢cation of cys-
teine-containing proteins and/or by binding to metallopro-
teins. Recently, the inhibitory e¡ect of NO or NO donors
on the catalytic activity of cruzipain, the major papain-like
cysteine proteinase from T. cruzi, has been reported. This
dose-dependent e¡ect was attributed to S-nitrosylation of
Cys25, a catalytic residue present in the active site of cruzipain
[16]. Ribonucleotide reductase inhibition has been suggested
to account for the cytostatic e¡ect of NO on T. brucei gam-
biense and T. brucei brucei. In addition the antiparasitic e¡ect
of NO has been also attributed [2] to inhibition of aconitase,
aldolase, cytochrome c oxidase and cytochrome P450.
Tissue tropism of T. cruzi varies and multiplication may
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occur in various non-phagocytic and phagocytic cell types.
However, in mammals there seems to be a general preference
for muscle, especially heart but also skeletal and smooth
muscle [1]. Although factors controlling tissue tropism are
poorly understood, it has been suggested that cardiomyocyte
mannose receptors localized at the sarcolemma mediate rec-
ognition and can be down-modulated by parasite infection
[17,18]. Interestingly, the preference of T. cruzi for cardiomyo-
cyte infection is positively correlated with the severity of the
lesions in the heart, generally more di¡used than in other
organs [1].
Here, we postulate that the preferential colonization of the
heart and skeletal muscle by T. cruzi depends on the role of
myoglobin (Mb) as a NO scavenger, protecting cellular respi-
ration [19]. The proposal of this novel function of Mb is based
on knowledge that ferrous oxygenated myoglobin (MbO2)
reacts rapidly and irreversibly with NO yielding nitrate and
ferric oxidized Mb (metMb) [20], which is reduced back to the
physiologically active form by an intracellular reductase [21].
Accordingly, the cycle may repeat over and over again and
the scavenging e¡ect may be considered ‘pseudo-enzymatic’
(Fig. 1). Given the high concentration of Mb in the heart
and skeletal muscle (0.2^0.4 mM), this reaction should e⁄-
ciently intercept NO and thereby reduce or abolish NO-re-
lated pathophysiological e¡ects. Since NO was shown
[26,27] to be a potent (albeit reversible) inhibitor of cyto-
chrome c oxidase, the terminal enzyme of the mitochondrial
respiratory chain, the scavenging function of Mb may lead to
e¡ective protection of cellular respiration and thus maintain
energy production in red muscle [19,28]. Along the same line
of thought, we propose that Mb may protect T. cruzi from the
adverse e¡ects of NO, including eventually inhibition of the
respiratory chain of the parasite, and thereby explain its pref-
erential localization in the cardiomyocytes.
This hypothesis has some predictive value. First of all, it is
expected that the severity of the chagasic heart disease would
signi¢cantly increase if tested with Mb knock-out mice which
display a benign phenotype [29,30]. Second, it may stimulate
an investigation to ¢nd out if T. brucei (the parasite respon-
sible for sleeping disease) is preferentially localized in the
brain areas which express the newly discovered neuroglobin
[31]. This Mb-like hemoprotein, expressed predominantly in
the frontal lobe, the subthalamic nucleus and the thalamus, is
likely to be irrelevant in O2 transport because of its low con-
centration (submicromolar), but may be involved in NO me-
tabolism. Moreover, it may demand some explanation to ac-
count for the reported localization of T. cruzi in smooth
muscle ¢bers [1], which are known to express Mb to a very
small extent [32]. In these cells, a role of Mb in NO metabo-
lism is possible but this hypothesis needs additional investiga-
tion. In this respect, it is of interest that some prokaryotes and
unicellular eukaryotes encode NO-inducible £avo- and trun-
cated hemoglobins that act as e¡ective NO scavengers to es-
cape host defenses and to survive in infected macrophages
[33,34].
An additional consideration may be in order. Plasmodium
falciparum is known to be killed by NO [35], and the mosquito
Anopheles stephensi, a natural vector of human malaria, limits
parasite development with inducible synthesis of NO [36].
Therefore, it seems likely that NO exerts an antiparasitic ac-
tivity in both the vector and the mammalian hosts. The postu-
lated protective e¡ect of MbO2 on T. cruzi colonizing cardi-
omyocytes may therefore be analogous to that assigned to
oxygenated hemoglobin in protecting intraerythrocytic Plas-
modia from the parasiticidal e¡ect of NO [37].
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